University Cancer Research Fund
The University Cancer Research Fund (UCRF) is a nation-leading investment to stimulate cancer research and reduce North Carolina’s leading cause of death. The Fund builds upon the exceptional research base at UNC Lineberger Comprehensive Cancer Center, the state’s only public, NCI-designated comprehensive cancer center.
UCRF’s Goal
To create a nation-leading cancer research effort and to reduce North Carolina’s cancer burden. UCRF is accomplishing these goals through:
- Discovery to better understand the causes and course of cancer.
- Innovation to create new and better ways to prevent, diagnose and treat cancer.
- Delivery of improved cancer care, screening and prevention across the state.
Latest News
-
Biological pathways provide evidence for how to overcome barriers limiting cancer immunotherapies
UNC Lineberger researchers have found a possible way to overcome barriers that block anti-cancer immune responses. Their findings could have implications for treating solid tumors, including breast and pancreatic cancer.
-
Protein could help identify head and neck cancers that require less intensive treatment
Adding detection of immune cell protein SYNGR3 to current protocols could lead to a more reliable way of determining which patients with head and neck cancer need less intensive treatment.
-
Pylayeva-Gupta published in Cell Reports Medicine
UNC Lineberger’s Yuliya Pylayeva-Gupta, PhD, was the corresponding author of a paper published in Cell Reports Medicine that examined how B cells might be reprogrammed to improve anti-tumor immune response in pancreatic cancer. The study was led by a former research associate, Rahul Mirlekar.
-
UNC Lineberger awards $1.1 million in developmental research grants
UNC Lineberger awarded 17 developmental research grants totaling nearly $1.1 million to faculty during the spring 2022 award cycle.
-
Using telehealth to regularly report symptoms improved overall well-being for patients with advanced cancer
Ethan Basch, MD, MSc, FASCO, reports that people with advanced cancer who reported their symptoms weekly using an electronic survey had better outcomes compared to those who were evaluated less frequently via in-person clinical visits.